Video Latest - ecancer

Venetoclax plus rituximab for patients with relapsed / refractory CLL

Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

$Venetoclax plus rituximab for patients with relapsed / refractory CLL ( Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )$

12 Dec 2017

Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

12 Dec 2017

Multiple myeloma analysis from ASH 2017

Dr Maxim Solovev and Dr Sung-Soo Yoon

12 Dec 2017

Multiple myeloma highlights from ASH 2017

Prof Meral Beksac - Ankara University Medical School, Ankara, Turkey

12 Dec 2017

ASH 2017: Immunotherapy for multiple myeloma

Prof Paul Richardson & Dr Wenming Chen

12 Dec 2017

Edoxaban versus dalteparin for venous thromboembolism associated with cancer

Dr Harry Büller - University of Amsterdam, Amsterdam, Netherlands

12 Dec 2017

Lenalidomide with rituximab for mantle cell lymphoma

Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New York, USA

11 Dec 2017

Combination chemotherapy for multiple myeloma

Dr Muzaffar Qazilbash - MD Anderson Cancer Center, Houston, USA

11 Dec 2017

Gilteritinib combination with induction and consolidation chemo in newly diagnosed AML

Dr Keith Pratz - Johns Hopkins University, Baltimore, USA

11 Dec 2017

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

11 Dec 2017

REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies

Dr Max Topp - University of Wurzburg, Wurzburg, Germany

11 Dec 2017

Results of the AML 12 trial

Dr Ana Garrido - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

11 Dec 2017

Video